Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110147 | 0.90 | HPGD (0.59) | MEN1KMT2ADRD2DRD5DRD3 | |
| SCHEMBL16110144 | 0.89 | MEN1 (0.52) | MEN1KMT2ADRD2DRD5DRD3 | |
| SCHEMBL7009115 | 0.89 | HPGD (0.62) | MEN1KMT2ADRD2DRD5DRD3 | |
| SCHEMBL14967395 | 0.87 | MAPT (0.51) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL3223793 | 0.82 | THRB (0.43) | MEN1KMT2ADRD2DRD5DRD3 | |
| SCHEMBL16110538 | 0.82 | MEN1 (0.46) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL28744553 | 0.82 | MEN1 (0.70) | MEN1KMT2ADRD2DRD3AR | |
| SCHEMBL29702930 | 0.82 | MEN1 (0.70) | MEN1KMT2ADRD2DRD3AR | |
| SCHEMBL16110129 | 0.80 | HPGD (0.42) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL15837517 | 0.75 | MEN1 (0.62) | MEN1KMT2ADRD2DRD3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-02-18 | — | — | US | disclosed |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-12-27 | — | — | US | disclosed |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-2780322-B1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | LIGAND PHARM INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20160374989-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9492430-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2016-11-15 | — | — | US | disclosed |
| US-20140296292-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369197-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-20160374989-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-20140296292-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-11413274-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-10111859-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-20210046045-A1 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
| US-10736875-B2 | Methods and compositions associated with the granulocyte colony-stimulating factor receptor | CSF3R, GMFG, CSF1R | MEN1 2845/4885KMT2A 2705/4885DRD2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.